Stock Events

BioInvent International AB 

SEK16.68
3
+SEK0.06+0.36% Today

Statistics

Day High
16.84
Day Low
16.62
52W High
30.4
52W Low
14
Volume
1,132
Avg. Volume
112,547
Mkt Cap
1.08B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26OctConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-1.71
-0.19
1.34
2.86
Expected EPS
-1.17
Actual EPS
-1

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BINV.ST. It's not an investment recommendation.

About

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Show more...
CEO
Dr. Martin Welschof Ph.D.
Employees
94
Country
SE
ISIN
SE0015244520
WKN
000A2QJRW

Listings